

DOPAMINE REDUCTION THERAPY: A NOVEL APPROACH TO REVERSE PARKINSON'S

2025


Phase 2 trial launches
(based on FDA engagement)

\$5M

Seed round
investment

Repurposed metyrosine (RB-190) —
identified to treat Parkinson's

RB-190 validated in **9 models** —
of Parkinson's



Rethinking Parkinson's

- + For the last 50 years, all Parkinson's therapies have focused on one simple approach – using medicines to increase brain levels of dopamine. However, this approach fails to reverse disease or disability.
- + Industry and academia are focusing on incrementally adjusting the dosing of these old-fashioned medicines to optimize blood levels and improve clinical effects. But these medicines don't fix the problem at any blood level.
- + Researchers are focusing on one possible cause of the disease as if the other contributing factors don't matter. Instead, we searched for a holistic cause of Parkinson's diseases.

RB-190 Is a Transformative, Ground-Breaking Alternative

- + Dr. Jonathan Sackner-Bernstein was curious how therapies that didn't fix the disease became standard of care. To understand, he applied analytic skills honed over 30+ years as a clinical trialist, a senior leader at the FDA and an insider at DARPA.
- + By translating the original 1960s publications, Sackner-Bernstein discovered a major flaw in their research methods. Dopamine was measured at the tissue level because it wasn't understood at the time that the clinically relevant measure is the cellular level. Realizing the cellular level was unknown energized Sackner-Bernstein.
- + First, he discovered that dopamine levels were excessive inside the brain cells that enable normal movement or cause Parkinson's.¹ And this excess dopamine is toxic; causing functional impairment and death of these brain cells.² The scientific literature shows that excess dopamine explains the pathology of Parkinson's.
- + Next, he discovered a drug (RB-190) that reduces cellular dopamine levels and reverses pathology – shown in 9 research models of Parkinson's disease.²
- + Now, Right Brain Bio is raising funds for Phase 2 clinical trials in Parkinson's launching in 2025 to prove that RB-190 restores function and reverses the disease.

¹ Sackner-Bernstein, *Journal of Parkinson's Disease* 2021, ² Sackner-Bernstein, *Journal of Neurology* 2023

The Team

Jonathan Sackner-Bernstein, MD: CEO & Founder
Keith A. Orris: BD & Lead Strategist
Tamim Braish, PhD: CMC/Manufacturing
Lead: Clinical Operations
Tim LaBua, JD, Faber: General Counsel
Anne Li, JD, Crowell: Intellectual Property
Angela Driscoll, MSA, Browne: Fractional Controller

Advisory Board

Roger Barker, MBBS, MRCP, PhD, Cambridge University
Paul Blake, MBBS, FRCP (1948-2024), formerly GSK and Cepharon
Jason Connor, PhD, ex-PCORI, ex-NINDS & FDA consultant
Jim Surmeier, PhD, Northwestern University